Poxel

company

About

Poxel is a research integrated pharmaceutical company that develops products for metabolic diseases.

  • 51 - 100

Details

Last Funding Type
Series A
Last Funding Money Raised
$21M
Industries
Biotechnology,Health Diagnostics,Pharmaceutical
Founded date
Jan 1, 2009
Number Of Employee
51 - 100
Operating Status
Active

Poxel is a dynamic biopharmaceutical company developing innovative drugs for metabolic diseases, with a focus on type 2 diabetes and non-alcoholic steatohepatitis (NASH). Based in Lyon, France, Poxel was spun out in 2009 from Merck Serono, a global leader in the field of metabolic disorders at that time.

They believe that targeting cellular energy regulation pathways for the treatment of metabolic diseases, including type 2 diabetes is of critical importance as disbalances are at the root of those diseases. All three of their clinical stage pipeline programs address significant targets in the energy metabolism pathways. Imeglimin, their lead program, targets mitochondrial dysfunction, mitochondria being the power station of the cell, PXL770 activates the adenosine monophosphate-activated protein kinase (AMPK), an important energy sensor, and PXL065 (DRX-065) inhibits the mitochondrial pyruvate carrier (MPC).

Funding Rounds

Number of Funding Rounds
Total Funding Amount
3
$34.50M €13M
Poxel has raised a total of $34.50M €13M in funding over 2 rounds. Their latest funding was raised on Sep 9, 2014 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Sep 9, 2014 Series B $13.50M 1 Detail
Dec 18, 2012 Series B €13M 1 Detail
Jul 8, 2010 Series A $21M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Poxel is funded by 2 investors. Kreos Capital and InnoBio Fund are the most recent investors.
Investor Name Lead Investor Funding Round
Kreos Capital Series B
InnoBio Fund Series B